Document Detail


Targeted agents in AML: much more to do.
MedLine Citation:
PMID:  17336253     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To what degree has targeted therapy succeeded in acute myeloid leukemia (AML)? Targeted therapy has become a buzzword, with its meaning lost from overuse. In chronic myeloid leukemia (CML), gastrointestinal stromal cell tumor, and a small subset of patients with non-small cell lung cancer, a validated target has been identified and a highly specific therapeutic agent has been developed. Targeted therapy generally requires a pathophysiological Achilles heel in a tumor that can be exploited by nontoxic therapy. In most cases, the validated target has been a tyrosine kinase enzyme critical for tumor growth and survival. Are similar "drugable" targets available in AML? While our understanding of the pathophysiology of AML has advanced over the past decade, and some potential targets have been identified, no single agent will likely produce a significant proportion of remissions. On the other hand, nascent attempts with mild success have been achieved, yielding hope that this strategy will bear real fruit in the future.
Authors:
Richard M Stone
Related Documents :
19738063 - The receptor tyrosine kinase ephb4 has tumor suppressor activities in intestinal tumori...
8733173 - The induction of counter-interactions in tumor cells as a basis for the development of ...
8765323 - Expression pattern of the von hippel-lindau protein in human tissues.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Best practice & research. Clinical haematology     Volume:  20     ISSN:  1521-6926     ISO Abbreviation:  Best Pract Res Clin Haematol     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-03-05     Completed Date:  2007-05-10     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  101120659     Medline TA:  Best Pract Res Clin Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  39-48     Citation Subset:  IM    
Affiliation:
Adult Leukemia Program, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, D 840 Boston, MA 02115, USA. rstone@partners.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Clinical Trials as Topic
Enzyme Inhibitors / therapeutic use*
Farnesyltranstransferase / antagonists & inhibitors
Gene Expression Regulation, Leukemic / drug effects
Humans
Leukemia, Myeloid / drug therapy*
Oncogenes / drug effects*
Translocation, Genetic / drug effects,  genetics
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors,  genetics
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; EC 2.5.1.29/Farnesyltranstransferase; EC 2.7.10.1/fms-Like Tyrosine Kinase 3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
Next Document:  Myelodysplasia: the good, the fair and the ugly.